Clinical Updates | Dr. Richard H. Mann

COVID-19 and Guillain–Barré Syndrome
By Dr. Mann
Blog, Clinical Update
May 4, 2020
On April 17, 2020, the online New England Journal of Medicine published the correspondence Guillain–Barré Syndrome Associated with SARS-CoV-2. The paper was authored by a team of Italian physicians [CLICK TO READ MORE]
COVID-19 and Peripheral Neuropathy
By Dr. Mann
Blog, Clinical Update
March 24, 2020
The American Academy of Otolaryngology and UK ENT, a professional membership body at The Royal College of Surgeons of England, announced recently on their websites that there is strong anecdotal [CLICK TO READ MORE]
Polyneuropathy
By Dr. Mann
Blog, Clinical Update
December 10, 2019
Polyneuropathy, the most common form of peripheral neuropathy, is a condition in which neurons of the peripheral nervous system dysfunction progressively, over time, in a length dependent manner–the [CLICK TO READ MORE]
Diabetic Polyneuropathy and Benfotiamine
By Dr. Mann
Blog, Clinical Update
September 27, 2019
During episodes of hyperglycemia, unlike most other cell types, the neurons and Schwann cells of the peripheral nervous system are unable to successfully prevent the rise of their internal glucose [CLICK TO READ MORE]
Prediabetic Neuropathy: Diagnosis and Treatment.
By Dr. Mann
Blog, Clinical Update
August 21, 2019
With estimates of the incidence of prediabetes in the USA at over 84 million people, prediabetes is an epidemic by any definition. It is also one of the leading causes of peripheral neuropathy with [CLICK TO READ MORE]
Prediabetes and Peripheral Neuropathy
By Dr. Mann
Blog, Clinical Update
July 25, 2019
Summary: The association between peripheral neuropathy and prediabetes, although not well known by clinicians, is well established in the scientific literature. It is estimated that up to 15 million [CLICK TO READ MORE]
On Treating Alcoholic Peripheral Neuropathy
By Dr. Mann
Blog, Clinical Update
June 24, 2019
Summary: Clinicians should consider the diagnosis of alcoholic polyneuropathy in patients who presently use alcohol excessively and patients who, while currently sober, have a history of such [CLICK TO READ MORE]
Type 2 Diabetes, Foot Ulcers and Cognition
By Dr. Mann
Blog, Clinical Update
May 21, 2019
Summary: Research group finds that type 2 diabetics with foot ulcers possess fewer cognitive resources than a matched group of type 2 diabetics without foot ulcers. The harmful impact of diabetes on [CLICK TO READ MORE]
Benfotiamine and Alzheimer’s Disease
By Dr. Mann
Blog, Clinical Update
April 17, 2019
If you are one of the thousands of physicians who use benfotiamine, a high potency lipid-soluble form of thiamine (vitamin B1), in the treatment of polyneuropathy, you are certainly aware of its [CLICK TO READ MORE]
Peripheral Neuropathy vs. Polyneuropathy
By Dr. Mann
Blog, Clinical Update
April 4, 2019
by Dr. Richard Mann, DABPS, ret, Chief Scientific Officer and Founder, Realm Labs®, sole US distributor of the NeuRemedy® line of benfotiamine products for the healthy function of the nerves in the [CLICK TO READ MORE]

NeuRemedy^®

Dr. Mann developed the formulation used in NeuRemedy^®, a safe and effective treatment to help relieve numbness, burning, tingling, and shooting pains in the feet and legs. NeuRemedy^®is currently dispensed by internationally by physicians to their patients suffering from these symptoms.

NeuRemedy^®is a nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains to the feet and legs.* Such symptoms are commonly associated with diabetes, advanced age, excess alcohol consumption, chemotherapy and/or nerve injury. The physician-formulated NeuRemedy^®line of products is sold exclusively to patients through physicians' offices.

NeuRemedy^®is licensed by Health Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.*

LEARN MORE ABOUT NEUREMEDY®

NeuRemedy®

NeuRemedy^®